REG - Cambridge Nutrition. - Trading Update

Cambridge Nutritional SciencesAnnouncement

27/05/2025 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250527:nRSa0607Ka&default-theme=true

RNS Number : 0607K  Cambridge Nutritional Sciences PLC  27 May 2025

 

The information contained within this announcement is deemed by the Company to
constitute inside information pursuant to Article 7 of EU Regulation 596/2014
as it forms part of UK domestic law by virtue of the European Union
(Withdrawal) Act 2018 as amended. Upon the publication of this announcement
via a Regulatory Information Service, this inside information is now
considered to be in the public domain.

 

Cambridge Nutritional Sciences plc

(the 'Company' or 'CNS')

Trading Update

 

CNS (AIM: CNSL), the specialist medical diagnostics company focused on
promoting a personalised and functional approach to health and nutrition, is
pleased to announce an update on the Group's trading for the year ended 31
March 2025, ahead of the release of its audited final results in July 2025.

Highlights:

·      Total Income expected to be c.£11.1m (2024: £9.9m) representing
a 12% increase on prior year. This includes £2.5m of exceptional income
recognised as a result of the successful outcome from the DHSC settlement.
Revenue excluding exceptional and other income is £8.3m (2024: £9.8m).

·      Gross profit margin of c.65% (2024: 61.9%).

·      Adjusted EBITDA(1) expected to show profit of £0.4m (2024:
profit of £0.2m).

·      Profit before tax is expected to be c.£1.6m (2024: £0.75m
loss).

·      Net cash balance of £4.9m (2024: £5.4m).

(1)Adjusted for exceptional items and share based payment charges.

2025 Financial performance:

Although total revenue is better than expected at £11.1m with the successful
resolution of the DHSC case, the Group expects to report revenue excluding
exceptionals and other income for the year ending 31 March 2025 at £8.3m.
This is a little lower than expected but has not impacted the full year
Adjusted EBITDA which is in line with market expectations.

Gross profit margin of c.65% (2024: 61.9%) has increased significantly with
yields enhanced following continued investment in production and operational
improvements and an ongoing focus to reduce scrap costs.

Overheads have been well managed with additional improvements in cost control
in all departments, whilst ensuring there is a concerted investment in the
sales and marketing team to help grow revenue in the future, via the creation
and development of an active pipeline.

This continued focus on efficiencies and cost control had resulted in an
expected Adjusted EBITDA(1) of £0.4m (2024: profit of £0.2m), which is
ahead of expectations.

Outlook:

The new financial year has started positively as the growing revenue pipeline
starts to flow through. This is early evidence of the more target focused
delivery of the revenue strategy for FY26 and is aided by a solid sales
position completed in the UK in FY25.

Other key markets for the Company include Europe, the USA and India where CNS
is developing some strong distributor relationships to drive demand from
laboratories as well as end users and healthcare practitioners.

Further investments in production and the laboratory are anticipated to
deliver additional improvements in yield and efficiency respectively. This
will help further improve the gross margin and increase capacity.

Finally, as the growing pipeline and markets of operation develop, the Company
has recognised the need to ensure people, processes and infrastructure
development is strengthened and as a result have expanded the leadership and
some broader teams to incorporate more experience and understanding of these
key areas.

The decision on 22 May 2025 by the Exeter Magistrates Court to fine the
Company £0.035m regarding historical breaches of Health & Safety
regulations in 2018 is seen positively as ending all known legal disputes,
allowing the Company to focus on improving business performance. This fine,
and associated costs, will be treated as exceptional in the reported year and
so have no impact on the key adjusted EBITDA performance indicator.

James Cooper, CEO, commented that: "I am pleased with our performance in
2025, delivering good solid profit even before we see the benefit of our new
sales pipeline coming through its long sales cycle. It is a very exciting time
for food sensitivity testing in a global market when gut health diagnostics
are showing signs of growth. I want to personally thank all our people and
acknowledge all their hard work and effort in the last year. Looking forward,
Cambridge Nutritional Sciences is in a very strong position from a product and
team perspective, with significant cash resources and the prospects for
revenue and profitability growth in 2026 and beyond."

 

 

Contacts:

 Cambridge Nutritional Sciences PLC                             www.cnsplc.com (http://www.cnsplc.com/)
 James Cooper, Chief
 Executive Officer

 Cavendish Capital Markets Limited                              Tel: 020 7220 0500
 Geoff Nash / Edward Whiley (Corporate Finance)
 Nigel Birks / Harriet Ward (ECM)

 

About Cambridge Nutritional Sciences plc

Cambridge Nutritional Sciences plc (AIM: CNSL) is a specialist medical
diagnostics company focused on industry-leading Health and Nutrition products.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFLFFREVIVFIE